RNS No 2903d
CELSIS INTERNATIONAL PLC
12th May 1998

Board Changes

Celsis International plc ('Celsis'), the microbial risk
management group, announces that Arthur Holden has today
resigned as Chief Executive Officer due to a conflict of
interest.  Mr Holden has informed the Board of his interest in
exploring options such as acquiring or taking the company
private.  The Board believes that it is now appropriate for
Celsis to have a Chief Executive who is resident in the UK.

The Board would like to take this opportunity to thank Mr
Holden for his contribution to the development of Celsis since
1994 and wish him the best for the future.

Following his departure, two further board changes have been
made: Jack Rowell has been appointed Acting Chief Executive,
relinquishing his role as Chairman, and will manage the
executive team and the Company's world-wide operations from its
Cambridge headquarters pending the appointment of a new Chief
Executive.  Dr. Chris Evans, currently a Non-Executive
Director, has been appointed Chairman and will focus on
strategic initiatives, commercial activities and development of
the new product pipeline.

Celsis announces its preliminary results for the year ended 31
March 1998 today.

Enquiries:

Celsis International plc
Dr Chris Evans, Chairman
Jack Rowell, Acting Chief Executive

0171 404 5959, (For today only)

Brunswick Group
Susan Gilchrist / James Garthwaite
0171 404 5959

END

BOANFXSAFDLPEEN
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.
Celadon Pharmaceuticals (LSE:CEL)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Celadon Pharmaceuticals Charts.